



**PRESS RELEASE**

16 January 2024 08:30:00 CET

## **AcouSort attends Advanced Therapies Week to extend its cell therapy network**

**The Phacilitate Network consists of over 1,800 industry experts within cell and gene therapy. For 20 years, the network has hosted the Advanced Therapies Week for knowledge sharing, relationship building and deal making. January 16-19, AcouSort will attend Advanced Therapies Week for the first time to interface with companies who are working on current and next generation technologies for cell and gene therapy.**

The decision to participate in Advanced Therapies Week follows a year where AcouSort made significant advances in the cell therapy area. Current collaborations and discussions have demonstrated that the Company's technology has a vital role to play in making the manufacturing of cell therapies much more efficient. During the meeting, AcouSort will give a poster presentation on its recently developed high-throughput cell processing solution targeting cell therapy applications.

*"Advanced Therapies Week is the primary networking meeting for industry leaders within cell and gene therapy. It specifically focuses on next generation solutions supporting the biotech industry, thus making the event an excellent opportunity to present the fantastic benefits of our technology,"* says Torsten Freltoft, AcouSort's CEO.

**FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:**

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: [torsten.freltoft@acousort.com](mailto:torsten.freltoft@acousort.com)

**ABOUT ACOUSORT**

*AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of-Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank.*